DDInter1141 DDInter167
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as the prevention of postmenopausal osteoporosis in women.
Megestrol acetate {u} (Compound) resembles {v} (Compound) Dydrogesterone
Megestrol acetate {u} (Compound) resembles {v} (Compound) Methyltestosterone
Megestrol acetate {u} (Compound) binds {v} (Gene) PGR
Megestrol acetate {u} (Compound) palliates {v} (Disease) breast cancer
Megestrol acetate {u} (Compound) is included by {v} (Pharmacologic Class) Progesterone Congeners
Megestrol acetate (Compound) resembles Dydrogesterone (Compound)
Megestrol acetate (Compound) resembles Methyltestosterone (Compound)
Megestrol acetate (Compound) binds PGR (Gene)
Megestrol acetate (Compound) palliates breast cancer (Disease)
Megestrol acetate (Compound) is included by Progesterone Congeners (Pharmacologic Class)